Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter
R3i & IAS Press Conference
Paris, France, 1 September 2019
The International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation announce a Joint Consensus Statement on Selective Peroxisome Proliferator Activated Receptor alpha Modulators (SPPARMα)
Watch Press Conference Webcasts...
R3i editorial
19 December 2019

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Focus on stroke: more input to address residual cardiovascular riskRead more...

Stroke is a leading cause of death worldwide, second only to ischaemic heart disease.
Yet, while there has been a decline in stroke mortality over the last three decades, stroke prevalence has increased, in part due to ageing populations and better risk factor management resulting in improved survival.
Thus, the burden posed by the morbidity and associated disability of recurrent stroke and associated cardiovascular events is substantial....
landmark study
19 December 2019

Treat Stroke to Target Study: Lower low-density lipoprotein cholesterol target after stroke reduces cardiovascular events Read more...

Current guidelines recommend intensive statin therapy for prevention of CV events following an ischaemic stroke or TIA,1 supported by results from the Stroke Prevention by Aggressive Reduction in Cholesterol Level (SPARCL) trial,2-4 and a recent meta-regression analysis.5 Despite this, guidelines do not specify target LDL-C...
focus on...
19 December 2019

ANGPTL3 monoclonal antibody in hypertriglyceridemia Read more...

Current therapeutic options for managing elevated TG are limited. Beyond statins, these include the fibrates (peroxisome proliferator-activated receptor alpha agonists) and omega-3 fatty acids; while effective, clinical use may be limited by side effects and drug-drug interactions.1 New options are clearly needed, particularly in the...
recent publication

Residual vascular risk in diabetes – will the SPPARM alpha concept hold the key?Read more...

Despite advances in best treatment targeting blood pressure, low-density lipoprotein (LDL) cholesterol and glycaemia (for microvascular disease), individuals with type...
recent publication

Metabolic syndrome recovery reduces risk for cardiovascular eventsRead more...

Recovery from the metabolic syndrome resulted in a corresponding decreased risk for major adverse cardiovascular events (MACE), according to a...
recent publication

ANGPTL3 variants and risk of ischaemic strokeRead more...

Variants of the ANGPTL3 gene, encoding angiopoietin-like 3 protein, can contribute to susceptibility to ischaemic stroke in the Chinese population...
recent publication

Remnant cholesterol associated with coronary atheroma progressionRead more...

In statin-treated patients with pre-existing coronary artery disease (CAD), higher remnant cholesterol levels were associated with greater coronary atheroma progression...
recent publication

Pemafibrate: promising effects in a mouse model of retinopathyRead more...

Results from this preclinical study suggest that pemafibrate, a novel SPPARMα (Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator), may prevent pathological...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARαMs in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.